Ad Header



The Pulse of the Pharmaceutical Industry

FDA staff says AcelRx opioid painkiller is not better than rivals

Written by: | | Dated: Wednesday, October 10th, 2018


(Reuters) – AcelRx Pharmaceuticals Inc’s opioid painkiller offers no apparent advantage to currently available therapies, staff reviewers of the U.S. Food and Administration said on Wednesday.

The FDA staff also highlighted that the small size of the oral Dsuvia pills makes it easier for patients to misplace them, potentially resulting in accidental use by others.

The drug is a new formulation that is meant to be taken orally through a pre-filled, single-dose applicator.

An advisory panel to the FDA will vote on the drug on Friday, before the regulator’s final decision by Nov. 3. The regulator generally follows the advice of its experts, but is not obliged to do so.


Reporting by Manas Mishra and Aakash Jagadeesh Babu in Bengaluru; Editing by Saumyadeb Chakrabarty


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom